Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.…
Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC
Cardiol Therapeutics (NASDAQ: CRDL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 18 employees.
The shares were at 0.8626 USD on 20 November 2026, down 17.1% over 52 weeks. Its 52-week range is 0.8417 USD to 2.340 USD: the price is 63.1% below the high and 2.5% above the low.
Its market capitalisation is 110.14M USD.
Cardiol Therapeutics reports return on equity of -189.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 25.97M CAD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 31 March 2027.